Calcium Channel Blockers May Reduce Peripheral Arterial Disease Risk

A relative risk reduction of 30% was found for PAD development in patients with hypertension.
A relative risk reduction of 30% was found for PAD development in patients with hypertension.

The following article is part of conference coverage from the 2018 AHA Scientific Sessions in Chicago, Illinois. MPR's staff will be reporting breaking news associated with research conducted by leading experts in cardiology. Check back for the latest news from AHA 2018.

CHICAGO — Calcium channel blockers (CCBs) may be effective in averting peripheral artery disease (PAD) in patients with hypertension, according to results presented at the Scientific Sessions of the American Heart Association, held November 10 to 12, 2018.

Researchers reviewed data from the MEDLINE and Cochran Central Register of Controlled Trials published between 1982 and 2018 to evaluate the effect of CCBs as the main prevention strategy for PAD in individuals with hypertension. 

Related Articles

Of the 928 trials reviewed, the researchers relied on 8 studies, which included 72,442 participants. Treatment group received either dihydropyridines or nondihydropyridines; control group received placebo or active treatment with an ACE-I, a beta-blocker, or a diuretic.

PAD events occurred in 547 (2%) individuals out of 27,737 who were receiving CCBs. In the control group, 1264 (3%) participants out of 43,894 experienced PAD events. Based on the random effect model, participants in the CCB group experienced a risk reduction of 30% (95% CI, 14%-42%; P<.001) compared with the control group.

"Our findings suggest that calcium channel blockers can be effective in preventing PAD in hypertensive patients," the researchers concluded.

Reference

Shetty S, Malik A, El Accaoui, R. Calcium channel blockers reduce incidence of peripheral arterial disease in patients with hypertension - a meta-analysis of randomized trials. Presented at AHA 2018; November 10-12, 2018; Chicago, Illinois. Abstract Sa3250/3250.